BioCardia (BCDA) vs Lipocine (LPCN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCardia (BCDA) has outperformed Lipocine (LPCN) over the past year, losing 25.4% versus a loss of 38.9%. Over five years, LPCN leads with a -90.0% price change compared with -97.6% for BCDA. BioCardia is the larger company by market cap ($16.1 million vs $15.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | LPCN |
|---|---|---|
| Share price | $1.07 | $1.88 |
| Market cap | $16.12M | $15.50M |
| 1-day change | +0.47% | -2.60% |
| YTD return | -15.20% | -75.97% |
| 1-year return | -25.35% | -38.92% |
| 5-year return | -97.59% | -89.95% |
| EPS (TTM) | $-0.64 | $-1.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $12.37 |
| 52-week low | $0.75 | $1.81 |
| Distance from 52-week high | -40.83% | -84.80% |
| Analyst consensus | none | none |
| Avg. price target upside | +1355.40% | +165.96% |
| Average volume | 282.05K | 1.72M |
| Shares outstanding | 15.14M | 8.24M |
| Employees | 17 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed LPCN by 13.6 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
BCDA vs LPCN FAQ
Which is bigger, BioCardia or Lipocine?
BioCardia (BCDA) is larger, with a market capitalization of $16.12M compared with $15.50M for Lipocine (LPCN).
Which stock has performed better over the past year, BCDA or LPCN?
BCDA returned -25.35% over the past 12 months, compared with -38.92% for LPCN (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Lipocine in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioCardia and Biotechnology: Pharmaceutical Preparations for Lipocine.